Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06617286 · ClinicalTrials.gov registry record · Phase 1
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
A Phase 1 study, sponsored by New York Medical College.
- Not yet
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT06617286 is a Phase 1 study that has not yet begun recruiting, run by New York Medical College. The registered enrollment target is 21 participants.
The verdict
NCT06617286, a Phase 1 study, has not yet begun recruiting, sponsored by New York Medical College.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
Interventions
- BIOLOGICAL CD30 CAR T-cell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2026-12-01 |
| Est. Completion | 2040-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06617286
The ClinicalTrials.gov registry entry for NCT06617286 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CD30 CAR T-cell is the first listed.
NCT06617286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06617286 about?
NCT06617286 is a clinical study titled "CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma". Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
What is the current status of trial NCT06617286?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2026-12-01. Estimated completion is 2040-12-31.
What interventions are being tested in trial NCT06617286?
The interventions under investigation include: CD30 CAR T-cell (BIOLOGICAL).
Who is sponsoring clinical trial NCT06617286?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.